flowchart LR A[Selection into cohort] -. ? .-> B[Survival];
CC34 Analysis
Analytic Plan
1. Flowchart to help understand sample sizes and selection
Gene expression?
Yes=1, No=0
Include reasons for why patients did not have gene expression data (MSK didn’t send, RNA extraction failed, Nanostring failed)
| Overall (N=929) |
|
|---|---|
| |
| Eligible for Nanostring | |
| Not Eligible | 14 (1.5%) |
| Eligible | 915 (98.5%) |
| Overall (N=929) |
|
|---|---|
| contrast | |
| No contrast | 764 (82.2%) |
| Contrast | 165 (17.8%) |
| Not Eligible (N=14) |
Eligible (N=915) |
Overall (N=929) |
|
|---|---|---|---|
| |||
| contrast | |||
| No contrast | 10 (71.4%) | 754 (82.4%) | 764 (82.2%) |
| Contrast | 4 (28.6%) | 161 (17.6%) | 165 (17.8%) |
| No Data (N=92) |
Has Data (N=837) |
Overall (N=929) |
|
|---|---|---|---|
| contrast | |||
| No contrast | 77 (83.7%) | 687 (82.1%) | 764 (82.2%) |
| Contrast | 15 (16.3%) | 150 (17.9%) | 165 (17.8%) |
Among all patients in RESOLVE:
flowchart LR A[All RESOLVE Patients<br />n=1,239] B[Sent to UNC<br />n=929] C[Nanostring eligible<br />n=915] D[Molecular data set<br />n=837] A --> B --> C --> D
Among patients in RESOLVE with non-contrast CTs:
flowchart LR A[All RESOLVE Patients<br />n=1,022] B[Sent to UNC<br />n=764] C[Nanostring eligible<br />n=754] D[Molecular data set<br />n=687] A --> B --> C --> D
2. Descriptive stats by whether patients have gene expression data
| Characteristic | Gene Expression | p-value2 | ||
|---|---|---|---|---|
| Overall, N = 1,2391 | No gene expr data (N = 402)1 |
Gene expr data (N = 837)1 |
||
| Age (cnts) | 58 (49, 66) | 58 (50, 66) | 58 (49, 66) | 0.9 |
| Sex | 0.4 | |||
| Female | 388 (31%) | 119 (30%) | 269 (32%) | |
| Male | 851 (69%) | 283 (70%) | 568 (68%) | |
| Race | 0.7 | |||
| Asian | 55 (4.4%) | 15 (3.7%) | 40 (4.8%) | |
| Black | 36 (2.9%) | 11 (2.7%) | 25 (3.0%) | |
| Other | 17 (1.4%) | 7 (1.7%) | 10 (1.2%) | |
| Unknown | 28 (2.3%) | 7 (1.7%) | 21 (2.5%) | |
| White | 1,103 (89%) | 362 (90%) | 741 (89%) | |
| Tumor grade | 0.11 | |||
| 1 | 29 (2.3%) | 15 (3.7%) | 14 (1.7%) | |
| 2 | 582 (47%) | 180 (45%) | 402 (48%) | |
| 3 | 533 (43%) | 173 (43%) | 360 (43%) | |
| 4 | 95 (7.7%) | 34 (8.5%) | 61 (7.3%) | |
| Tumor stage | 0.028 | |||
| 1 | 795 (64%) | 248 (62%) | 547 (65%) | |
| 2 | 63 (5.1%) | 30 (7.5%) | 33 (3.9%) | |
| 3 | 381 (31%) | 124 (31%) | 257 (31%) | |
| Tumor size | 4.00 (2.50, 6.00) | 4.00 (2.50, 6.50) | 4.00 (2.50, 6.00) | 0.5 |
| Ever smoked | >0.9 | |||
| Ever | 604 (49%) | 197 (49%) | 407 (49%) | |
| Never | 635 (51%) | 205 (51%) | 430 (51%) | |
| BMI | 29.6 (26.4, 33.4) | 29.4 (26.2, 33.5) | 29.6 (26.6, 33.4) | 0.5 |
| History of diabetes | 193 (16%) | 53 (13%) | 140 (17%) | 0.11 |
| History of hypertension | 674 (54%) | 217 (54%) | 457 (55%) | 0.8 |
| History of hyperlipidemia | 469 (38%) | 147 (37%) | 322 (38%) | 0.5 |
| CKD at baseline | 0.3 | |||
| CKD | 239 (19%) | 84 (21%) | 155 (19%) | |
| No CKD | 1,000 (81%) | 318 (79%) | 682 (81%) | |
| SMI | 54 (46, 61) | 54 (46, 61) | 54 (46, 61) | >0.9 |
| SMD | 38 (32, 43) | 38 (32, 44) | 37 (32, 43) | 0.3 |
| VATI | 64 (41, 90) | 62 (40, 86) | 66 (42, 92) | 0.090 |
| VATD | -96 (-100, -91) | -96 (-100, -91) | -96 (-100, -91) | 0.2 |
| SATI | 73 (52, 105) | 72 (52, 104) | 74 (52, 106) | 0.5 |
| SATD | -101 (-105, -97) | -101 (-105, -97) | -102 (-106, -98) | 0.092 |
| 1 Median (IQR); n (%) | ||||
| 2 Wilcoxon rank sum test; Pearson’s Chi-squared test | ||||
| Characteristic | Gene Expression among non-contrast | p-value2 | ||
|---|---|---|---|---|
| Overall, N = 1,0221 | No gene expr data (N = 335)1 |
Gene expr data (N = 687)1 |
||
| Age (cnts) | 58 (49, 66) | 58 (50, 66) | 58 (49, 66) | 0.5 |
| Sex | 0.3 | |||
| Female | 320 (31%) | 97 (29%) | 223 (32%) | |
| Male | 702 (69%) | 238 (71%) | 464 (68%) | |
| Race | 0.5 | |||
| Asian | 43 (4.2%) | 10 (3.0%) | 33 (4.8%) | |
| Black | 32 (3.1%) | 9 (2.7%) | 23 (3.3%) | |
| Other | 12 (1.2%) | 5 (1.5%) | 7 (1.0%) | |
| Unknown | 24 (2.3%) | 6 (1.8%) | 18 (2.6%) | |
| White | 911 (89%) | 305 (91%) | 606 (88%) | |
| Tumor grade | 0.5 | |||
| 1 | 26 (2.5%) | 12 (3.6%) | 14 (2.0%) | |
| 2 | 481 (47%) | 155 (46%) | 326 (47%) | |
| 3 | 435 (43%) | 141 (42%) | 294 (43%) | |
| 4 | 80 (7.8%) | 27 (8.1%) | 53 (7.7%) | |
| Tumor stage | 0.049 | |||
| 1 | 658 (64%) | 207 (62%) | 451 (66%) | |
| 2 | 52 (5.1%) | 25 (7.5%) | 27 (3.9%) | |
| 3 | 312 (31%) | 103 (31%) | 209 (30%) | |
| Tumor size | 3.95 (2.50, 6.00) | 4.00 (2.50, 6.50) | 3.90 (2.50, 5.90) | 0.6 |
| Ever smoked | 0.4 | |||
| Ever | 501 (49%) | 170 (51%) | 331 (48%) | |
| Never | 521 (51%) | 165 (49%) | 356 (52%) | |
| BMI | 29.7 (26.5, 33.6) | 29.4 (26.2, 33.7) | 29.8 (26.6, 33.6) | 0.5 |
| History of diabetes | 163 (16%) | 44 (13%) | 119 (17%) | 0.086 |
| History of hypertension | 567 (55%) | 185 (55%) | 382 (56%) | >0.9 |
| History of hyperlipidemia | 390 (38%) | 122 (36%) | 268 (39%) | 0.4 |
| CKD at baseline | 0.2 | |||
| CKD | 208 (20%) | 76 (23%) | 132 (19%) | |
| No CKD | 814 (80%) | 259 (77%) | 555 (81%) | |
| SMI | 53 (46, 61) | 53 (46, 61) | 53 (46, 62) | 0.7 |
| SMD | 37 (31, 43) | 38 (31, 43) | 37 (31, 43) | 0.7 |
| VATI | 65 (43, 91) | 63 (43, 86) | 66 (43, 93) | 0.2 |
| VATD | -97 (-100, -92) | -97 (-100, -92) | -97 (-101, -92) | 0.3 |
| SATI | 73 (52, 105) | 71 (52, 103) | 74 (52, 107) | 0.5 |
| SATD | -102 (-106, -98) | -101 (-105, -97) | -102 (-106, -98) | 0.053 |
| 1 Median (IQR); n (%) | ||||
| 2 Wilcoxon rank sum test; Pearson’s Chi-squared test; Fisher’s exact test | ||||
3. KM Plots and Cox PH models by whether patients have gene expression data available
| Characteristic | HR1 | 95% CI1 | p-value |
|---|---|---|---|
| Gene Expr Data DFS | 0.77 | 0.55, 1.06 | 0.11 |
| Gene Expr Data OS | 0.82 | 0.50, 1.35 | 0.4 |
| Gene Expr Data DFS (non-contrast) | 0.85 | 0.60, 1.22 | 0.4 |
| Gene Expr Data OS (non-contrast) | 1.03 | 0.59, 1.78 | >0.9 |
| 1 HR = Hazard Ratio, CI = Confidence Interval | |||